{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-206247","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.477670+00:00","generated_at":"2026-06-12T02:00:32.893051+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atea Pharma Q2 net loss $28.2M; progresses COVID-19 & HCV trials","bullets":["Net loss of $28.2M in Q2 2023 (EPS -$0.34) compared to $31.3M loss in Q2 2022.","Cash, equivalents and marketable securities $608.1M, down $38.6M from Dec 2022.","Phase 3 SUNRISE-3 trial amended: eligibility broadened, target enrollment ~2,200; topline expected mid-2024.","Phase 2 HCV study of bemnifosbuvir+ruzavir dosing; initial data from lead-in cohort (~60 pts) expected 4Q23.","R&D expenses rose to $22.1M from $19.9M YoY, driven by trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-206247","json":"https://secwatch.observer/filing/0001193125-23-206247.json","markdown":"https://secwatch.observer/filing/0001193125-23-206247.md","text":"https://secwatch.observer/filing/0001193125-23-206247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/0001193125-23-206247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/d534379d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:00:32.893051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ada89210cfc0f81fa2f8c6be701713ee85de598","claim":"Atea Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended June 30, 2023 and other matters described in the press release.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312523206247/0001193125-23-206247-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}